Clinical Trials in MS in which BNAC Served as a Clinical Core Lab

 

2020

  • Zivadinov R, Dwyer MG, Carl E, et al. Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Ther Adv Neurol Disord 2020;13:1756286420970754. [Open article]
  • Zivadinov R, Bergsland N, Millman M, Jakimovski D, Ramasamy D, Weinstock-Guttman B, Zarif M, Freedman M, Hunter S, Cohan S, Edwards K, Steingo B, Zabad R, Baker M, Belkin M, Repovic P, Mazhari A, Chase A, Silversteen J, Smith D, Negroski D, Feinberg M, Newman S, Pardo G, Riolo J, Silva D, DeepGRAI Study Group. (2020) Feasibility of thalamic atrophy measurement in clinical routine using artificial intelligence: Results from multi-center, longitudinal study in RRMS patients. 8th Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020:P0577
  • Beadnall H, Weinstock-Guttman B, Wang C, Hagemeier J, Bergsland N, Jakimovski D, Ramanathan M, Ly L, Dwyer M, Schweser F, Hardy T, Benedict R, Barnett M, Zivadinov R (2020) Fingolimod therapy in real world relapsing MS patients: Cognition, quantitative MRI and deep gray matter quantitative susceptibility mapping. 8th Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 September 11-13,:P0874

2019

  • Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C and Weinstock-Guttman B (2019). "Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis." Mult Scler Relat Disord 36: 101388. [Open article]
  • Fuchs TA, Ziccardi S, Dwyer MG, Charvet LE, Bartnik A, Campbell R, Escobar J, Hojnacki D, Kolb C, Oship D, Pol J, Shaw MT, Wojcik C, Yasin F, Weinstock-Guttman B, Zivadinov R and Benedict RHB (2019). "Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study." Mult Scler Relat Disord 34: 103-111. [Open article]
  • Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D and Weinstock-Guttman B (2019). "Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study." J Clin Med 8(3). [Open article]
  • Gupta S, Fellows K, Weinstock-Guttman B, Hagemeier J, Zivadinov R, Ramanathan M (2019) Marijuana Use by Patients with Multiple Sclerosis. Int J MS Care 21:57-62 [Open article]
  • Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E and Dwyer MG (2019). "A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS." AJNR Am J Neuroradiol 40(3): 446-452. [Open article]
  • Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M and Cohan S (2019). "Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study." J Comp Eff Res 8(5): 305-316. [Open article]
  • Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M and Zivadinov R (2019). "Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study." J Neurol 266(4): 866-875. [Open article]
  • Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, Barnett Y, Barnett MH, Kyle KA, Zivadinov R, Ma KC, Milliken ST, Sutton IJ and Ma DDF (2019). "Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis." J Neurol Neurosurg Psychiatry 90(5): 514-521. [Open article]
  • Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B and Group M-MS (2019). "Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study." Mult Scler Relat Disord 27: 65-73. [Open article]
  • Sprenger T, Lebrun-Frenay C, Vermersch P, Park M, Chinchilla D, McCombe P, Lincoln J, Bergsland N, Dwyer M, Kappos L, Cavalier S, Roesch N, Guce M, Poole E, Zivadinov R (2019) Investigating the ecfect of teriflunomide on diffuse cortical grey matter volume loss int he phase 3 TOPIC study. 5th Congress of thr European Academy of Neurology (EAN), Oslo, Norway June 29-July 2

2018

  • Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C and Weinstock-Guttman B (2018). "The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study." CNS Drugs 32(8): 763-770. [Open article]
  • Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B and investigators M-M (2018). "Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS." J Neuroimaging 28(4): 399-405. [Open article]
  • Zivadinov R, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Kolodny S, Silva D, Medin J, Weinstock-Guttman B and group M-Ms (2018). "No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study." Curr Med Res Opin 34(8): 1431-1440. [Open article]
  • Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D and Weinstock-Guttman B (2018). "Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures." J Neurol Sci 388: 175-181. [Open article]
  • Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D and Weinstock-Guttman B (2018). "Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study." J Neurol Sci 387: 152-156. [Open article]
  • Kim S, Chang L, Weinstock-Guttman B, Gandhi S, Jakimovski D, Carl E, Zivadinov R and Ramanathan M (2018). "Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study." J Altern Complement Med 24(6): 596-602. [Open article]
  • Zivadinov R, Hagemeier J, Bergsland N, Tavazzi E and Weinstock-Guttman B (2018). "Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study." Eur J Neurol 25(3): 584-e536. [Open article]
  • Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R and Group M-MS (2018). "Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study." CNS Drugs 32(1): 75-84. [Open article]
  • Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D and Group M-MS (2018). "Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS." AJNR Am J Neuroradiol 39(2): 289-295. [Open article]

2017

  • Zivadinov R, Khan N, Medin J, Christoffersen P, Price J, Korn JR, Bonzani I, Dwyer MG, Bergsland N, Carl E, Silva D and Weinstock-Guttman B (2017). "An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study." J Neuroimaging 27(3): 339-347. [Open article]
  • Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S and Zivadinov R (2017). "Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study." Mult Scler 23(6): 818-829. [Open article]
  • Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, Tyblova M, Ramasamy D, Zivadinov R and Horakova D (2017). "Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?" Mult Scler 23(2): 242-252. [Open article]
  • Weinstein D, Boyko A, Pugliese L, Tang H, Lanfear D, Zivadinov R, BA. F (2017) A novel once daily oral treatment, decreased lesion burden of patients with relapsing-remitting course of multiple sclerosis (RRMS) in a randomized, double-blind, phase 2b, multicenter study. 69th Annual Meeting of American Academy of Neurology, Boston, MA April 22-28:S:1770 [Open article]
  • Sergott R, Bryan M, Moster M, Zivadinov R (2017) Defining the anatomical & physiological hierarchy of neuro-degeneration of the afferent visual system in Multiple Sclerosis: A cross-sectional study with spectral domain OCT, visual fields multifocal ERG, EDSS, regional & whole brain atrophy. 7th Joint  Congress of the European and American Committee for Treatment and Research in Multiple Sclerosis, Paris, France October 25-28:P1090

2016

  • Greenberg SJ, Zivadinov R, Lee-Kwen P, Sharma J, Planter M, Umhauer M, Glenister N and Bakshi R (2016). "Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease." Ther Adv Neurol Disord 9(2): 105-117. [Open article]
  • Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG and Weinstock-Guttman B (2016). "Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years." Eur J Neurol 23(6): 1101-1109. [Open article]
  • Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E and Horakova D (2016). "A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients." Mult Scler 22(13): 1709-1718. [Open article]
  • Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D and Zivadinov R (2016). "Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation." J Neurol Neurosurg Psychiatry 87(9): 937-943. [Open article]
  • Zivadinov R, Cha C, Buckle G, Aldridge J, Haas G, Reed J, Hughes B (2016) Patient real-world clinical, neurological, tolerability, and safety outcomes for dimethyl fumarate and interferon beta-1a 44 µg subcutaneously three times weekly: A retrospective study using propensity score stratification and matching (PROTRACT). 2nd  Congress of the European Committee for Treatment and Research in Multiple Sclerosis, London, UK September 14-17:P1184

2015

  • Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B and Markovic-Plese S (2015). "Immunologic and MRI markers of the therapeutic effect of IFN-beta-1a in relapsing-remitting MS." Neurol Neuroimmunol Neuroinflamm 2(6): e176. [Open article]
  • Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR and Khan O (2015). "The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis." J Neuroimaging 25(6): 989-995. [Open article]
  • Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F and Weinstock-Guttman B (2015). "A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis." Ther Adv Neurol Disord 8(2): 59-70. [Open article]
  • Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V and Khan O (2015). "Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis." J Neurol 262(3): 648-653. [Open article]
  • Zivadinov R, Ramasamy D, Melia R, Hagemeier J, Durfee J, Dwyer M, Carl E, Kolb C, Hojnacki D, Weinstock-Guttman B (2015) Voxel-wise magnetization transfer imaging study of effects of fingolimod (Gilenya®) on remyelination and demyelination in patients with relapsing forms of multiple sclerosis. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, Spain October 7-10:EP1326 [Open article]

2014

  • Siddiqui AH, Zivadinov R, Benedict RH, Karmon Y, Yu J, Hartney ML, Marr KL, Valnarov V, Kennedy CL, Ramanathan M, Ramasamy DP, Dolic K, Hojnacki DW, Carl E, Levy EI, Hopkins LN and Weinstock-Guttman B (2014). "Prospective randomized trial of venous angioplasty in MS (PREMiSe)." Neurology 83(5): 441-449. [Open article]
  • Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F and Weinstock-Guttman B (2014). "Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study." PLoS One 9(3): e91098. [Open article]
  •  

2013

  • Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, Zhao Z and Duda P (2013). "A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes." J Neurovirol 19(4): 351-358. [Open article]
  • Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R and Group GS (2013). "Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis." Ann Neurol 73(6): 705-713. [Open article]
  • Zivadinov R, Havrdova E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Carl E, Kalincik T and Horakova D (2013). "Thalamic atrophy is associated with development of clinically definite multiple sclerosis." Radiology 268(3): 831-841. [Open article]
  • Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Potts JA, Kalincik T, Havrdova E and Horakova D (2013). "Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years." AJNR Am J Neuroradiol 34(10): 1931-1939. [Open article]
  • Zivadinov R, Magnano C, Galeotti R, Schirda C, Menegatti E, Weinstock-Guttman B, Marr K, Bartolomei I, Hagemeier J, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Beggs C, Salvi F and Zamboni P (2013). "Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study." J Vasc Interv Radiol 24(6): 829-838. [Open article]

2012

  • Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, Bergsland N, Minagar A and Weinstock-Guttman B (2012). "Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study." Neurol Res 34(8): 761-769. [Open article]
  • Zivadinov R, Hojnacki D, Hussein S, Bergsland N, Carl E, Durfee J, Dwyer MG, Kennedy C and Weinstock-Guttman B (2012). "Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study." Int J Mol Sci 13(5): 5659-5673. [Open article]
  • Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG (2012) Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Front Biosci (Elite Ed) 4:1496-1504 [Open article]
  • Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N and Weinstock-Guttman B (2012). "Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNbeta-1a in multiple sclerosis." Mult Scler 18(8): 1125-1134. [Open article]
  • Zamboni P, Galeotti R, Weinstock-Guttman B, Kennedy C, Salvi F and Zivadinov R (2012). "Venous angioplasty in patients with multiple sclerosis: results of a pilot study." Eur J Vasc Endovasc Surg 43(1): 116-122. [Open article]

2011

  • Zivadinov R, Hussein S, Stosic M, Durfee J, Cox JL, Hashmi K, Abdelrahman N, Garg N, Dwyer MG and Weinstock-Guttman B (2011). "Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study." Pathophysiology 18(1): 61-68. [Open article]
  • Zivadinov R, Dwyer M, Bergsland N, Hussein S, Durfee J, Ramasamy D, Cherneva M, Willis L, Cox J, Kennedy C, Margolin D, Rizzo M, Palmer J (2011) Effect of alemtuzumab vs.  interferon beta-1a on brain atrophy in patients with early, active relapsing-remitting multiple sclerosis. Neurology 76:P05.042, A388

2010

  • Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stuve O, Greenberg BM, Racke MK and Zivadinov R (2010). "A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis." Ther Adv Neurol Disord 3(1): 15-28. [Open article]

2009

  • Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M and Horakova D (2009). "Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis." Mult Scler 15(8): 965-976. [Open article]
  • Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, Vaneckova M and Zivadinov R (2009). "Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study." J Neurol Sci 282(1-2): 112-119. [Open article]

2008

  • Zivadinov R, Zorzon M, De Masi R, Nasuelli D and Cazzato G (2008). "Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis." J Neurol Sci 267(1-2): 28-35. [Open article]
  • Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M and Zivadinov R (2008). "Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study." J Neurol Neurosurg Psychiatry 79(4): 407-414. [Open article]

2007

  • Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M and Zorzon M (2007). "Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy." Mult Scler 13(4): 490-501. [Open article]

2006

  • Chadha K, Weinstock-Guttman B, Zivadinov R, Bhasi K, Muhitch J, Feichter J, Tamano-Blanco M, Abdelrahman N, Ambrus J, Sr., Munschauer F and Ramanathan M (2006). "Interferon inhibitory activity in patients with multiple sclerosis." Arch Neurol 63(11): 1579-1584. [Open article]
  • Santos R, Weinstock-Guttman B, Tamano-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F, 3rd and Ramanathan M (2006). "Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies." J Neuroimmunol 176(1-2): 125-133. [Open article]

 

2001

  • Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G and Zorzon M (2001). "Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS." Neurology 57(7): 1239-1247. [Open article]